




The Value of Earlier Diagnostic Insight

In selected fertility cases, sperm DNA fragmentation may be a contributing factor that is not assessed by standard semen analysis. Earlier consideration of sperm DNA testing may support more informed clinical discussions, reduce diagnostic uncertainty, and help clinicians review the most appropriate next steps within the wider fertility pathway.



Failed Cycles

Repeated treatment cycles without full diagnostic assessment



Incomplete Diagnostic Information

Clinical governance considerations



Time Lost

Potential treatment delays may occur after unsuccessful cycles

[Discover the Potential Value of Examen Testing](#)

[Learn More](#)

Financial Considerations in Repeated Treatment Cycles

When sperm DNA fragmentation is not assessed, patients may undergo repeated cycles without a full understanding of possible contributing male-factor issues. Each IVF cycle involves significant cost — and without investigating a possible contributing factor, cumulative financial and emotional challenges may increase. These figures represent example cost ranges, subject to clinic pricing and patient pathway.

£8K

Per IVF Cycle

Example maximum cost of a single IVF cycle

£16K

Repeated IVF Expenditure

Example cumulative cost across repeated cycles without full diagnostic assessment

£6K

Prior IUI Expenditure

Example cost of IUI cycles before further investigation is considered




Patients invest significant time and resources in fertility treatment



Repeated unexplained outcomes may affect patient confidence


Investigations, Recurrent Pregnancy Loss & Incomplete Diagnostic Information

Recurrent miscarriage investigations involve significant cost per patient — a challenge that may be compounded when possible contributing factors remain unexplored. Without sperm DNA fragmentation testing in appropriate cases, clinicians may not fully assess possible male-factor contributions to recurrent pregnancy loss.



£5,000

Example maximum cost of recurrent miscarriage investigations per patient



Clinical Governance

Where clinically indicated, sperm DNA testing may support a more complete diagnostic pathway.

As awareness of sperm DNA fragmentation grows within the clinical community, clinics may wish to consider how male-factor testing fits within their clinical governance and patient counselling protocols.

Patient Confidence and Continuity of Care

The combined effect of unexplained treatment outcomes, incomplete diagnostic pathways, and patient attrition creates challenges clinics may benefit from considering. Diagnostic thoroughness is both a clinical and commercial consideration.



Unexplained Treatment Outcomes

Repeated cycles without a clear diagnostic rationale may affect patient confidence. In a competitive fertility market, unexplained outcomes may affect patient confidence and referral discussions.



Patient Lost to a Competitor

Patient retention may have commercial implications, depending on clinic fees and treatment pathway. When patients feel their concerns are not fully investigated, they may seek care elsewhere — making thorough diagnostics both a clinical and commercial consideration.

Time Matters in Fertility Care

For patients trying to conceive, time is an important consideration. Unsuccessful cycles may delay further decision-making and treatment planning — making earlier diagnostic assessment a relevant clinical consideration in appropriate cases.



3–6 Months

Potential treatment delay following an unsuccessful IVF or IUI cycle



1 Year+

Cumulative potential delay across multiple unsuccessful cycles — important where time is clinically relevant



Earlier Answers

Earlier diagnostic assessment may support earlier discussion of appropriate treatment options

The Potential Value of Examen Testing

Examen provides a clinically validated sperm DNA testing service designed to support clinician-led fertility assessment. At less than 10% of the cost of a single IVF cycle, one test may provide additional information to support clinician-led treatment planning in appropriate cases.



<10% of IVF Cost

Testing may help reduce diagnostic uncertainty and support earlier clinical decision-making

The test is designed to integrate into existing clinical workflows, with end-to-end logistics including a dry shipper, certified courier, and flexible collection options.



AUC 0.93

Reported AUC in a specified study population, supporting informed, evidence-based clinical discussions



Clinical Evidence Supporting Diagnostic Insight

These figures highlight a diagnostic consideration in standard fertility workups. Standard semen analysis does not assess sperm DNA integrity — and in selected cases, clinicians may benefit from additional information to support their assessment.



33% vs 13%

In one published study, lower sperm DNA fragmentation was associated with higher live birth rates than higher sperm DNA fragmentation. This association does not prove that testing improves live birth rates.



7 in 10 Men

In one study cohort, a proportion of men with normal semen parameters had elevated sperm DNA damage — suggesting that semen parameters alone may not provide a complete assessment of sperm DNA integrity.



AUC 0.93

Reported AUC in a specified study population, providing additional data to support clinician-led treatment planning and patient counselling.

EXTEND®: Assessment of Double-Strand DNA Breaks

Examen's EXTEND® technology is designed to identify double-strand DNA breaks in sperm — a clinically relevant form of sperm DNA damage. Unlike single-strand break assays, EXTEND® is designed to detect damage reported in published research to be associated with fertilisation, embryo development, and recurrent pregnancy loss outcomes.


Double-Strand Detection

EXTEND® is designed to identify double-strand breaks — a form of sperm DNA damage not specifically differentiated by many standard SDF approaches.



Minimum 0.1M/ml

Accessible for patients with severe oligospermia and those providing surgically retrieved sperm (SSR) samples — supporting assessment in selected complex male-factor cases where sample criteria are met.



Potential to Support Earlier Decision-Making

By incorporating Examen into the diagnostic pathway in appropriate cases, clinics may be able to support earlier decision-making in selected cases — helping clinicians consider whether additional investigations may be appropriate before further treatment. The logistics are designed to support clinic integration.



Test with Examen

Early DNA fragmentation screening designed to integrate into existing clinical workflows



Identify Fragmentation

Determine sperm DNA status to support discussion of treatment options based on the wider clinical picture



Treatment Planning Discussion

For patients with high fragmentation, this may support clinician-led consideration of options such as further male-factor assessment, lifestyle review, or ART protocol discussion where appropriate

The end-to-end logistics service — including dry shipper, certified courier, and flexible collection scheduling — ensures integration is straightforward, regardless of clinic size or location.

Better-Informed Decisions. Clearer Counselling. Stronger Diagnostic Pathways.

Examen may support a more informed fertility diagnostic pathway. Patients receive clinically relevant information to support clinician-led discussions — and clinics may benefit from more complete diagnostic assessment, support patient communication, continuity of care, and clinical governance.



Informed Treatment Planning

Sperm DNA testing may support treatment planning in cases where sperm DNA fragmentation is clinically relevant, and may help reduce diagnostic uncertainty.



Better Decisions

Validated diagnostic information gives clinicians additional evidence to support patient counselling and clinical decision-making.



Continuity of Care

Patients who feel thoroughly investigated and well-supported may be more likely to continue care at your clinic — supporting continuity of care and clinic service planning.



Clinical Governance

Comprehensive diagnostics may support clinical governance and documentation, and strengthen your clinic's standing in an increasingly competitive market.

[Request an Examen Demo](#)

[Download Clinical Evidence](#)

This information is intended for educational and healthcare professional use only. Sperm DNA testing should be interpreted by a qualified clinician alongside semen analysis, female-factor assessment, reproductive history, embryo development data, and other relevant investigations. The test does not diagnose infertility on its own and does not guarantee fertilisation, pregnancy, live birth, miscarriage reduction, shorter treatment time, reduced treatment cost, improved clinic retention, or reduced legal risk.